Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Enterprise Value (2020 - 2026)

Ovid Therapeutics' Enterprise Value history spans 6 years, with the latest figure at -$69.6 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 32.5% year-over-year to -$69.6 million; the TTM value through Dec 2025 reached -$69.6 million, down 32.5%, while the annual FY2025 figure was -$69.6 million, 32.5% down from the prior year.
  • Enterprise Value reached -$69.6 million in Q4 2025 per OVID's latest filing, down from -$25.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$25.6 million in Q3 2025 to a low of -$233.1 million in Q1 2021.
  • Average Enterprise Value over 5 years is -$113.6 million, with a median of -$100.7 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: crashed 414.29% in 2021, then skyrocketed 59.61% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$187.8 million in 2021, then soared by 32.83% to -$126.1 million in 2022, then increased by 16.1% to -$105.8 million in 2023, then surged by 50.34% to -$52.6 million in 2024, then tumbled by 32.5% to -$69.6 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Enterprise Value are -$69.6 million (Q4 2025), -$25.6 million (Q3 2025), and -$30.7 million (Q2 2025).